Individualized immunotherapy for early-stage Hodgkin lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial aims to establish a personalized first-line treatment for early-stage unfavorable classical Hodgkin lymphoma (cHL) using checkpoint inhibition. The approach focuses on the use of Tislelizumab, a PD-1 blockade, which has shown effectiveness in relapsed cHL and may reduce the need for conventional chemotherapy and radiotherapy. By targeting patients who achieve early metabolic complete remission, the study seeks to minimize treatment-related side effects and improve quality of life for predominantly young patients. The trial will evaluate the safety and efficacy of this treatment strategy in a defined patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18-60 for the main trial cohort
* Age ≥ 61 years and eligible for AVD as determined by CIRS-G score and investigator for the exploratory cohort
* First diagnosis of treatment-naïve cHL
* Early-stage unfavorable disease (i.e. stage IA, IB and IIA with risk factors a-d, stage IIB with risk factors c-d):

  1. large mediastinal mass
  2. extranodal lesion(s)
  3. elevated erythrocyte sedimentation rate
  4. ≥ 3 nodal areas

     Exclusion Criteria:
* Presence of nodular-lymphocyte predominant Hodgkin lymphoma, grey-zone lymphoma and/or central nervous system involvement of lymphoma

Where it's running

• 1st Department of Medicine, Cologne University Hospital
  Cologne, Germany Recruiting

Study contacts

• Principal investigator: Paul Broeckelmann, Dr. — 1st Department of Medicine, Cologne Universit Hospital
• Study coordinator: Michael Fuchs
• Email: ghsg@uk-koeln.de
• Phone: +49221478

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Blood ctDNA testing to monitor treatment in children and young adults with classical Hodgkin lymphoma

  This project tests whether a blood test that detects circulating tumor DNA can monitor treatment response and help predict relapse in children and young adults with classical Hodgkin lymphoma.

  Recruiting Assistance Publique - Hôpitaux de Paris · Paris · NCT07356882

• Sintilimab combined with AVD chemotherapy for treating pediatric Hodgkin lymphoma

  This study is testing if a new immunotherapy combined with standard chemotherapy can help children and teens with low-to-intermediate risk Hodgkin lymphoma feel better and improve their treatment results.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT06848569

• Assessing Prognosis in Hodgkin Lymphoma

  This study is trying to find better ways to predict how Hodgkin Lymphoma will progress in patients who have finished treatment or have had a relapse, using new tools and tests to help personalize their care.

  Recruiting at 12 sites Azienda USL Reggio Emilia - IRCCS · Milan, MI and 11 other locations · NCT06822855

• Using Brentuximab Vedotin to treat newly diagnosed Classical Hodgkin Lymphoma in young patients

  This study is testing if a new treatment with Brentuximab vedotin can help young patients with newly diagnosed classical Hodgkin lymphoma feel better while reducing the need for chemotherapy and radiation.

  Recruiting Phase 2/3 Children's Cancer Group, China · Shanghai · NCT06563245

• Healthy Lifestyle Plan for Lymphoma Survivors

  This study is testing whether a special health plan that includes lifestyle changes and nutrition advice can help lymphoma survivors feel better after they've been in remission for a while.

  Recruiting at 34 sites Fondazione Italiana Linfomi - ETS · Ancona, Ancona and 39 other locations · NCT05934084

• Combining pembrolizumab with chemotherapy for relapsed Hodgkin lymphoma

  This study is testing if adding pembrolizumab to standard chemotherapy can help people with relapsed Hodgkin lymphoma feel better and have fewer side effects.

  Recruiting Phase 2 University of Cologne · Cologne · NCT04838652

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.